Omnicare's Series A and Series B Trust PIERS to Accrue Contingent Interest

Omnicare's Series A and Series B Trust PIERS to Accrue Contingent Interest

ID: 307289

(Thomson Reuters ONE) -


CINCINNATI, October 18, 2013 - Omnicare, Inc. (NYSE: OCR) announced today that
for the period from September 15, 2013 to December 14, 2013 its Series A and
Series B Trust Preferred Income Equity Redeemable Securities (NYSE: OCR.PRA and
OCR.PRB) (the "Trust PIERS") will, subject to the terms of the Trust PIERS,
accrue contingent interest at a rate of 0.125% of the average trading price of
the Trust PIERS for the five trading days ended September 12, 2013, in addition
to the continued accrual of regular cash interest.  Contingent cash interest,
which Omnicare has determined to be approximately $0.085 per $50 stated
liquidation amount of Trust PIERS, will be payable to holders of the Trust PIERS
as of the record date, which is December 13, 2013.  The payment of contingent
cash interest is expected to be made on December 16, 2013.

About Omnicare

Omnicare, Inc., a Fortune 500 company based in Cincinnati, Ohio, provides
comprehensive pharmaceutical services to patients and providers across the
United States.  As the market-leader in professional pharmacy, related
consulting and data management services for skilled nursing, assisted living and
other chronic care institutions, Omnicare leverages its unparalleled clinical
insight into the geriatric market along with some of the industry's most
innovative technological capabilities to the benefit of its long-term care
customers.  Omnicare also provides key commercialization services for the bio-
pharmaceutical industry through its Specialty Care Group.  For more information,
visit www.omnicare.com.


# # #


Contact:
Patrick C. Lee
(513) 719-1507
patrick.lee(at)omnicare.com



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:




(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Omnicare via Thomson Reuters ONE
[HUG#1736439]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Actelion receives US FDA approval of Opsumit (macitentan) for the treatment of pulmonary arterial hypertension Online Reputation Protection Through Creating Positive Assets
Bereitgestellt von Benutzer: hugin
Datum: 18.10.2013 - 22:30 Uhr
Sprache: Deutsch
News-ID 307289
Anzahl Zeichen: 2421

contact information:
Town:

Covington, KY



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 186 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Omnicare's Series A and Series B Trust PIERS to Accrue Contingent Interest"
steht unter der journalistisch-redaktionellen Verantwortung von

Omnicare (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Omnicare



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z